CKD试验中的性别差异:代表性及心肾保护治疗的效果
结果显示女性入组比例中位数33.1%,52项试验女性入组少于预期,汇总EDD为-0.17(95%CI -0.20至-0.14),且仅23.6%试验报告性别特异性结局。历史扩展至117项试验未发现女性代表性随时间改善。
要点
- 女性在CKD心肾保护治疗试验中代表性不足,汇总EDD为-0.17(95%CI -0.20至-0.14)。
- II期设计及需蛋白尿入选与女性代表性更差相关,糖尿病入选及女性第一作者与差异较小相关。
- 仅23.6%试验报告性别特异性心血管和肾脏结局,证据基础性别代表性未见改善。
核心结论
- 女性在心肾保护治疗试验中持续代表性不足,性别特异性结局报告有限。
- 历史基准分析表明CKD药物治疗进展未伴随证据基础性别代表性的可证明改善。
研究设计与样本
- 女性代表性用入组差异差(EDD)量化,即观察女性比例减预期比例(基于GBD CKD患病率性别匹配),随机效应荟萃分析汇总。
主要发现
- 女性入组比例中位数33.1%,52项试验(94.5%)入组女性少于预期。
- 汇总EDD为-0.17(95%CI -0.20至-0.14),所有干预类别均为负值。
- 荟萃回归中,II期设计及蛋白尿要求与女性代表性更差相关,糖尿病要求及女性第一作者与较小差异相关。
- 仅13项试验(23.6%)报告性别特异性结局。
- 扩展至117项试验未发现女性代表性随时间改善的统计学证据,38项关键CKD试验均入组女性少于预期。
临床怎么用
- 解读心肾保护治疗CKD证据时需注意女性代表性不足可能限制结果外推。
- 关注试验是否报告性别特异性结局以指导女性患者个体化治疗。
局限性
- 研究为荟萃流行病学分析,EDD基于GBD患病率估计匹配试验特征,可能存在未测量混杂。
- 历史分析为观察性扩展,未提供因果关系证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women comprise a substantial proportion of the chronic kidney disease (CKD) population and differ from men in disease phenotype, progression, and treatment exposure. Underrepresentation of women and limited sex-specific reporting may therefore reduce the generalizability of evidence from contemporary CKD trials. METHODS: We conducted a meta-epidemiological study of randomized trials evaluating sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists in adults with CKD. Female representation was quantified using the enrollment disparity difference (EDD), defined as the observed proportion of female trial participants minus the expected proportion derived from sex-specific Global Burden of Disease CKD prevalence estimates matched to trial population characteristics. Trial-level EDDs were pooled using random-effects meta-analysis. Meta-regression was used to examine trial-level correlates of EDD. Historical analyses extended the cohort to earlier cardiorenal pharmacotherapies to evaluate temporal trends, with pivotal CKD trials examined descriptively. Reporting of sex-specific cardiovascular and kidney outcomes was also assessed. RESULTS: Fifty-five randomized trials were included. Median female enrollment was 33.1%, and 52 trials (94.5%) enrolled fewer women than expected. The pooled EDD was -0.17 (95% CI, -0.20; -0.14), with negative estimates across all intervention classes. In meta-regression, phase II design and albuminuria requirement were associated with greater female underrepresentation, whereas diabetes requirement and female first authorship were associated with smaller enrollment disparity, including after adjustment for other key trial characteristics. Sex-specific outcomes were reported in 13 trials (23.6%). Extension to 117 trials provided no statistically supported evidence of improvement in female representation over time, including after adjustment for intervention class; all 38 pivotal CKD trials enrolled fewer women than expected. CONCLUSIONS: Women remain underrepresented in cardiorenoprotective therapy trials, with limited sex-specific outcome reporting. Historical benchmarking indicates that successive advances in CKD pharmacotherapy have not been accompanied by demonstrable improvement in the sex representativeness of the evidence base.
引用
- Bellos I, Athanasiou M, Nikita KS, et al. Sex in CKD trials: representation and treatment effects of cardiorenoprotective therapies. Nephrol Dial Transplant. 2026. PMID: 42671242. doi:10.1093/ndt/gfag199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。